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Abstract 
Background and Purpose  
Elevated plasma homocysteine levels are associated with stroke. However, this might be a 
reflection of bias or confounding, as trials have failed to demonstrate an effect from 
homocysteine-lowering in stroke patients, although a possible benefit has been suggested in 
lacunar stroke. Genetic studies could potentially overcome these issues as genetic variants are 
inherited randomly and are fixed at conception.  
Therefore we tested the homocysteine levels-associated genetic variant MTHFR C677T for 
association with MRI-confirmed lacunar stroke and compared this with associations with 
large artery and cardioembolic stroke subtypes.  
Methods 
We included 1359 MRI-confirmed lacunar stroke cases, 1824 large artery stroke cases, 1970 
cardioembolic stroke cases, and 14448 controls, all of European ancestry. Furthermore, we 
studied 3670 ischemic stroke patients in whom white matter hyperintensities volume was 
measured. We tested MTHFR C677T for association with stroke subtypes and white matter 
hyperintensities volume. Because of the established association of homocysteine with 
hypertension, we additionally stratified for hypertension status.  
Results 
MTHFR C677T was associated with lacunar stroke (p=0.0003) and white matter 
hyperintensities volume (p=0.04), but not with the other stroke subtypes. Stratifying the 
lacunar stroke cases for hypertension status, confirmed this association in hypertensives 
(p=0.0002), but not in normotensives (p=0.30).  
Conclusions 
MTHFR C677T was associated with MRI-confirmed lacunar stroke, but not large artery or 
cardioembolic stroke. The association may act through increased susceptibility to, or 
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interaction with, high blood pressure. This heterogeneity of association might explain the lack 
of effect of lowering homocysteine in secondary prevention trials which included all strokes.  
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Elevated plasma homocysteine levels (tHcy) have been consistently associated with the risk 
of ischemic stroke in observational studies.
1
 Moreover, experimental studies suggest that 
increases in total homocysteine aggravates vascular disease.
2
 However some clinical trials 
that investigated the benefit of lowering tHcy with B vitamins to reduce the risk of stroke 
have been negative.
3-6
 In contrast, a recent large primary prevention trial in China, CSPPT, 
which recruited only hypertensive patients, demonstrated a beneficial effect in reducing risk 
of stroke.
7
 Possible reasons for this conflicting evidence include insufficient stroke 
phenotyping particularly if homocysteine is a predominant risk factor for one type of stroke, 
dietary folate fortification reducing tHcy in populations in which trials have been performed, 
interactions between treatment and risk factors, and insufficient treatment duration.  
 
A subtype specific effect, with elevated homocysteine primarily increasing risk for small 
vessel disease (SVD) stroke, has been suggested by both epidemiological data and secondary 
analysis of clinical trials. Case-control studies have suggested elevated homocysteine is 
primarily a risk factor for lacunar stroke,
8, 9
 and that there may be heterogeneity even within 
this subtype, with strongest associations in those SVD cases with multiple lacunar infarcts 
and confluent leukoaraiosis on MRI.
10
  Most previous clinical trials that investigated the 
benefit of lowering homocysteine studied stroke as a combined event lumping together all 
different aetiologies (i.e. haemorrhage and ischaemic, and ischaemic stroke subtypes). A 
secondary analysis in the  VITATOPS trial,
3
 found a borderline treatment effect in patients 
with lacunar stroke (HR 0.80 (95% CI 0.67–0.96)), while an MRI VITATOPS substudy 
found vitamin lowering therapy was associated with reduced white matter lesion volume 
progression in patients with severe white matter lesions.
11
 A further possibility is that 
elevated homocysteine may interact with certain cardiovascular risk factors, and treatment 
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effect may only be detected if these interactions are taken into account; of possible relevance 
the positive CSPTT trial was only performed in hypertensive individuals. 
 
Another possible explanation for the conflicting epidemiological and clinical trial data is that 
the association between homocysteine and risk of ischemic stroke is a reflection of reverse 
causality or residual confounding i.e. elevated tHcy does not play a causal role in stroke 
pathogenesis but are merely non-causally associated with an increased risk of stroke. Genetic 
studies have the potential to overcome these issues, by using genetic variants associated with 
elevated tHcy as a proxy for tHcy, because the inheritance of genetic variants is random and 
not influenced by confounding factors. The most often studied genetic variant, showing the 
strongest association with increased tHcy, is the C677T polymorphism of the methylene 
tetrahydrofolate reductase (MTHFR) gene (rs1801133).
12-14
 Case-control studies that 
investigated the association of the MTHFR C677T variant with stroke yielded inconsistent 
results, which is likely due to small sample sizes and the varying stroke phenotypes studied. 
Meta-analyses have produced conflicting results with an association reported between 
MTHFR and ischaemic heart disease and stroke in one study but not with stroke in another.
12, 
15
 Studies using detailed MRI-based stroke phenotyping have suggested the association may 
be confined to, or strongest in, patients with the lacunar stroke subtype.
10 
 
Based on the above data we hypothesised that the MTHFR C677T variant may be a specific 
risk factor for SVD but not for other stroke subtypes. Lacunar infarcts are small and 
frequently not seen on CT and therefore MRI is important for accurate diagnosis.
16
 Therefore 
we determined whether the MTHFR polymorphism is associated with MRI confirmed lacunar 
stroke. We compared these results with similar analyses from patients with cardioembolic 
and large artery stroke. In addition we determined whether the same polymorphism was 
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associated with MRI white matter hyperintensities, another marker of SVD. Because of the 
known association of hypertension with both tHcy and stroke, and in view of the positive 
results from the recent CSPTT study, we also stratified the analyses by hypertension status. 
 
 
Methods 
Stroke populations 
We included 1359 MRI defined lacunar stroke cases from the UK young lacunar stroke DNA 
study, the Leuven Stroke Study (LSS) and the MRI-confirmed lacunar stroke collaboration 
(MCLSC), including cohorts from the UK, Germany, Italy and Australia (Online-only Data 
Supplement Table I). Lacunar stroke was defined as a clinical lacunar syndrome
17
 with an 
anatomically corresponding lacunar infarct on MRI (subcortical infarct <=15 mm in 
diameter). All MRI scans were centrally reviewed by one physician (HSM). Exclusion 
criteria were: stenosis > 50% in the extra- or intracranial cerebral vessels; cardioembolic 
source of stroke, defined according to the TOAST (Trial of Org 10172 in Acute Stroke 
Treatment) criteria
18
 as high or moderate probability; subcortical infarct > 15 mm in 
diameter, as these can be caused by embolic mechanisms (striatocapsular infarcts); any other 
specific cause of stroke (e.g. lupus anticoagulant, cerebral vasculitis, dissection, monogenic 
forms of stroke e.g. CADASIL). Large-artery and cardioembolic stroke cases were obtained 
from GENESIS, LSS, MCLSC and the Wellcome Trust Case Control Immunochip 
Consortium (WTCCC2-Immunochip) including cohorts from the UK, Germany, Belgium, 
Italy, Sweden, Poland, Austria and Australia. Cases were classified into stroke subtypes 
according to the pathophysiological Trial of Organization 10172 in Acute Stroke Treatment 
(TOAST) classification,
18
 using clinical assessment as well as brain and vascular imaging 
where available. Hypertension was defined as prescription of antihypertensives before stroke 
or systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg >1 week post 
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stroke. 14448 ancestry-matched controls were obtained from the same geographical location 
as the cases in each group. A description and characteristics of all cohorts are given in the 
Online-only Data Supplement Table I.  
 
White Matter Hyperintensity volumes population 
The white matter hyperintensity (WMH) volumes population (n=3,670) was derived from the 
International Stroke Genetics Consortium (ISGC) WMH collaboration (ISGC-WMH). This 
collaboration measured WMH volumes in patients with ischaemic stroke from the UK, Italy, 
Belgium, Germany, Australia and USA (Online-only Data Supplement Table II). Inclusion 
criteria were: >18 years of age, self-reported European ancestry, and a diagnosis of ischaemic 
stroke. Exclusion criteria were any other cause of white matter disease including CADASIL, 
vasculitis, and demyelinating and mitochondrial disorders. MRI scans were acquired as part 
of routine clinical practice for evaluation of ischemic stroke. Fluid attenuated inversion 
recovery (FLAIR) sequences were primarily used for leukoaraiosis analysis; however, in their 
absence, T2 sequences were used. All scans were quantitatively graded to obtain a WMH 
volume, which was normalised for intracranial volume. WMH volume was measured in the 
hemisphere contralateral to the infarct and doubled to obtain whole brain volumes. Patients 
with bilateral non-lacunar infracts were excluded. All neuroimaging analyses have been 
previously described.
19
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Genotyping 
Direct genotyping of rs1801133 was performed in all cohorts except WTCCC2-Immunochip 
using commercially available arrays from Affymetrix or Illumina. In WTCCC2-Immunochip, 
rs1801133 was imputed from the 1000 Genomes integrated variant set (March 2012) using 
IMPUTE v2.
20
 The SNP was imputed with high accuracy (imputation info-score=0.91). The 
SNP passed genotyping frequency thresholds (>97%) and was in Hardy-Weinberg 
equilibrium in all groups. To control for population stratification, individuals were removed 
that did not segregate with Hapmap II European populations based on ancestry informative 
principal component analysis using EIGENSTRAT or multidimensional scaling in PLINK 
and ancestry-informative covariates were included in all analyses.
21, 22
  
 
Statistical analysis 
In each cohort, logistic regression was performed to test for association of MTHFR C677T 
with MRI-defined lacunar stroke, cardioembolic stroke and large artery stroke, assuming an 
additive model and adjusting for ancestry-informative principal components.  
For each cohort the association between WMH volume and MTHFR C677T was determined 
by performing linear regression of WMH volume on genotype dosages. Results across all 
cohorts were combined using a fixed-effects inverse variance weighted meta-analysis 
method. Subsequently we repeated the analyses for MRI-defined lacunar stroke and WMH 
volume stratified by hypertension status.  
We set our p-value threshold for the main analyses to p<0.05 and then used a Bonferroni-
corrected value (p=0.005) to assess significance in secondary analyses. 
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Results 
Stroke analyses 
MTHFR C677T was significantly associated with lacunar stroke (OR 1.20 (95% CI 1.09-
1.33), p=0.0003), but not with large-artery stroke (OR 1.01 (95% CI 0.93-1.08), p=0.88) or 
cardioembolic stroke 1.03 (95%CI 0.96-1.11), p=0.44) (Figure 1). 
In the lacunar stroke cases the association was most pronounced in homozygotes (OR 1.48 
(95% CI 1.20-1.84) for TT versus CC, p=0.0003; OR 1.17 (95% CI 1.01-1.36) for CT versus 
CC, p=0.03)).  
The overall prevalence of hypertension in the lacunar stroke cases was 72.6%. There were no 
differences in the prevalence of hypertension according to MTHFR genotype (72.0% in CC, 
73.4% in CT and 71.2% in TT). Stratifying the lacunar stroke cases for hypertension status 
demonstrated the association of MTHFR C677T with lacunar stroke was present in 
hypertensives (OR 1.24 (95% CI 1.11-1.38), p=0.0002), but not in normotensives (OR 1.09 
(95% CI 0.92-1.29), p=0.30. In hypertensive and normotensive cases separately, the 
association of MTHFR C677T with lacunar stroke was again most pronounced in 
homozygotes (Table 1). 
 
WMH Volumes analyses 
MTHFR C677T was significantly associated with WMH volume (OR 1.06 (95% CI 1.01-
1.11), p=0.04) (Figure 2). In the secondary analyses in which we stratified by hypertension 
status, there was a borderline association for either hypertensive cases (OR 1.06 (95% CI 
1.00-1.13), p=0.05) although this did not pass the Bonferroni-corrected threshold, while there 
was no association in normotensive cases (OR 1.02 (95% CI 0.95-1.11), p=0.57).   
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Discussion 
In the present study we showed that the tHcy-associated genetic variant MTHFR C677T was 
associated with lacunar stroke risk and cerebral SVD, but not for large artery or 
cardioembolic stroke and that this association was restricted to patients with hypertension. 
Thereby this study supports the hypothesis that homocysteine is a risk factor for specifically 
SVD and not for the other stroke subtypes.  
 
Previous genetic association studies linking homocysteine to ischaemic stroke have produced 
conflicting results.
15
 Such candidate studies may be influenced by publication bias, which is 
reduced in large multicentre GWAS studies. A recent analysis of 18 SNPs associated with 
tHcy reported equivocal results in 12389 ischemic stroke cases (METASTROKE).
23
 There 
was no association between any SNPs associated with tHcy and all ischaemic stroke, or large 
artery or cardioembolic subtypes, consistent with this study. However one SNP was 
associated with lacunar stroke (rs9369898, MUT) but no association was found with the 
MTHFR polymorphism.  
 
Our study is the first large scale study to include MRI based phenotyping of lacunar stroke. 
The majority of stroke cases in previous studies have relied on CT brain imaging in 
combination of a diagnosis of a lacunar stroke syndrome. In up to 50% of cases a clinical 
lacunar syndrome is caused by pathologies other than SVD.
24
  
 
Another possible reason for the conflicting results between different studies is dietary folic 
acid fortification in certain populations. This was present in some cohorts in METASTROKE 
and might have attenuated any association with MTHFR C677T in METASTROKE.
15
 In the 
present study, folic acid fortification was not used in any of the included stroke cohorts, but 
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was used in some of the included WMH volume cohorts. The association shown between 
MTHFR C677T and WMH volume in the present study might have been attenuated by the 
inclusion of these folic acid fortified cohorts. 
 
The SVD specific effect of MTHFR C677T in the present study might reflect the effects of 
increased tHcy in SVD patients with this genetic variant. Although, we did not assess tHcy in 
the present study and therefore cannot draw conclusions on this association in the present 
study, previous studies support this hypothesis of possible SVD specific effect of increased 
tHcy.  Secondary analyses of the VITATOPS trial which suggested that homocysteine 
lowering therapy may be associated with improved outcome in SVD (both lacunar stroke and 
WMH) but not in other stroke subtypes.
3
 In the VITATOPS trial, in which lacunar stroke 
subtyping was largely based on a clinical stroke syndrome with CT imaging, a borderline 
significant reduction in recurrent stroke occurred in patients with SVD; based on our results 
one could hypothesise that this treatment effect might be stronger in MRI confirmed lacunar 
stroke. Consistent with this specific effect in SVD are the results of an MRI substudy in 359 
individuals from VITATOPS; while no association was found in the group as a whole, in a 
sub-analysis of patients with MRI evidence of severe SVD at baseline, B-vitamin 
supplementation was associated with a significant reduction in white matter hyperintensities 
volume change.
11
 Two meta-analyses on previous genetic association studies linking MTHFR 
with WMH on MRI could not confirm an association between MTHFR and WMH.
25, 26
 
Individual studies that were included in these meta-analyses had only small number of 
patients and it was suggested that much larger studies would be needed to detect an 
association.
25
 In the present study we included twice as many subjects as the largest study in 
the previous meta-analyses that assessed WMH on a dichotomous scale and three times as 
many subjects as the study that assessed WMH volume.     
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We found that the association of MTHFR C677T with lacunar stroke was restricted to 
hypertensive individuals. One possible explanation for this finding exclusively in 
hypertensive individuals might be that the association acts through increased susceptibility to, 
or interaction with, high blood pressure. Interestingly, the recent large primary prevention 
CSPTT trial showed a benefit of homocysteine lowering therapy in reducing stroke risk in 
hypertensive individuals from a population in which folic acid fortification was not 
occurring.
7
  
 
The major strength of our study is the confirmation of all lacunar strokes by MRI and the 
relatively large sample size. Furthermore, the approach of using a genetic proxy for tHcy 
reduces the likeliness of reversed causality and residual confounding compared to previous 
observational studies. The relationship between tHcy and stroke in observational studies 
might be confounded by unmeasured or not adequately measured factors (for example other 
dietary factors) that are causally associated with stroke. In contrast, genetic studies rely on the 
fact that genetic variants are fixed from conception and are not influenced by other traits. 
Moreover, the stroke cohorts were derived from countries in which folic acid fortification 
was not implemented at the time of stroke, which maximised the chances of demonstrating an 
effect for MTHFR C677T. We also included an analysis of WMH volume in ischaemic stroke 
patients. Stroke patients represent an enriched population in whom WMH are increased. It 
has been shown however that the genetic factors underlying WMH in ischemic stroke 
patients appear to be similar to those in population based studies of WMH.
19
 
A potential limitation of the present study is that we did not have independent replication 
cohorts available to validate our findings and therefore future studies are warranted to 
confirm these interesting findings. Furthermore, although MTHFR C677T is strongly 
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associated with tHcy in other studies,
12, 14
 we could not also directly assess the association of 
tHcy with stroke subtype in the present study because tHcy measurements were not available 
in all of our cohorts. 
In summary, we showed that MTHFR C677T was associated with lacunar stroke in 
hypertensive individuals, supporting a possible causal role for homocysteine in the 
pathogenesis of cerebral SVD. Our results suggest that any future trials investigating the 
benefit of lowering homocysteine in stroke patients should focus on the SVD subtype, and 
that they should incorporate MRI based diagnosis.  
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Figure 1. Forest plot for the association of MTHFR C677T with stroke subtypes 
 
The size of the box is inversely proportional to the estimate variance of the effect estimator.  
Abbreviations: LSS, Leuven Stroke Study; GENESIS, Genetic Risk factors for Leukoaraiosis 
study; MCLSC, MRI-confirmed lacunar stroke collaboration; WTCCC2-Immunochip, 
Wellcome Trust Case Control Immunochip Consortium  
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Figure 2. Forest plot for the association of MTHFR C677T with WMH 
 
 
 
The size of the box is inversely proportional to the estimate variance of the effect estimator. 
Abbreviations: ASGC, Australian Stroke Genetics Collaborative; GENESIS, Genetic Risk 
factors for Leukoaraiosis study; ISGS, Ischemic Stroke Genetics Study; LSS, Leuven Stroke 
Study; MGH, Massachusetts General Hospital; SGUL, St Georges University of London; 
SWISS, Sibling with Ischaemic Stroke Study; WTCCC2, Wellcome Trust Case-Control 
Consortium 2 
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Table 1. Association between MTHFR C677T genotypes and MRI-defined lacunar stroke 
 
 MTHFR 
genotype 
OR p 
 All lacunar stroke  
CT versus CC 1.17 (95% CI 1.01-1.36) 0.03 
TT versus CC 1.48 (95% CI 1.20-1.84) 0.0003 
 Hypertensive lacunar stroke  
CT versus CC 1.19 (95% CI 1.01-1.40) 0.04 
TT versus CC 1.58 (95% CI 1.25-2.00) 0.0001 
 Normotensive lacunar stroke  
CT versus CC 1.07 (95% CI 0.84-1.37) 0.58 
TT versus CC 1.23 (95% CI 0.85-1.78) 0.28 
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Cohorts description 
UK Young Lacunar Stroke DNA Study (DNA Lacunar) 
DNA Lacunar is a multicentre cohort study, which constitutes a large DNA resource of 
young patients with well phenotyped lacunar stroke and stroke-free community controls. 
Between 2005 and 2012, 1030 white patients of European ancestry with lacunar stroke, aged 
< 70 years, were recruited from 72 specialist stroke centres throughout the UK. All patients 
underwent brain MRI, imaging of the carotid arteries and ECG. Echocardiography was 
performed when appropriate. All MRI’s and clinical histories were reviewed centrally by one 
experienced stroke physician. 
970 Unrelated Caucasian controls, free of clinical cerebrovascular disease, were obtained by 
random sampling from general practice lists from the same geographical location as the 
patients. Sampling was stratified for age and sex. 
 
MRI-confirmed ischemic stroke collaboration (MCISC) 
Wellcome Trust Case-Control Consortium 2 (WTCCC2)  
The WTCCC2 samples were genotyped as part of the WTCCC 2 ischemic stroke study. 
Stroke cases were recruited from three centres in the UK (St. George's University London, 
Oxford and Edinburgh) and one centre in Germany, University and Klinikum Großhadern, 
Ludwig-Maximilians-University, Munich 
WTCCC2-UK: The St George’s Stroke Study consecutively recruited ischemic stroke patients 
attending cerebrovascular services in London between 1995 and 2008. All patients had 
clinically relevant diagnostic workup performed, including brain imaging with computed 
tomography (CT) and/or magnetic resonance imaging (MRI) as well as ancillary diagnostic 
investigations including duplex ultrasonography of the carotid and vertebral arteries, 
echocardiography, 
Holter monitoring, magnetic resonance angiography (MRA), CT-angiography 
(CTA) and blood tests. The Oxford Vascular Study recruited patients with acute ischemic 
stroke or transient ischemic attack (TIA) with evidence of infarction on brain imaging 
between 2002 and 2008 as part of a population-based stud. All cases were phenotyped by one 
experienced stroke neurologist with review of original imaging. The Edinburgh Stroke Study 
prospectively recruited consecutive stroke inpatients and outpatients between 2002 and 2005. 
An experienced stroke physician assessed each patient as soon as possible after the stroke, 
prospectively recording demographic and clinical details, including vascular risk factors and 
results of brain imaging and other investigations 
WTCCC2-Germany: The Munich study recruited consecutively between 2002 and 2008, 
from a single Stroke Unit with a high rate of MR imaging (>80%) (n=1383). All subjects 
were over 18 years of age, of self-reported European ancestry and with a diagnosis of 
ischemic stroke classified according to TOAST by an experienced neurologist or stroke 
physician. All patients had brain imaging as well as ancillary diagnostic investigations where 
clinically relevant. 
Controls for the UK samples were drawn from shared WTCCC controls obtained from the 
1958 Birth Cohort. This is a prospectively collected cohort of individuals born in 1958 
(http://www.b58cgene.sgul.ac.uk/), and ascertained as part of the national child development 
study (http://www.cls.ioe.ac.uk/studies.asp?section=000100020003). Data from this cohort 
are available as a common control set for a number of genetic and epidemiological studies. 
For the German samples controls were Caucasians of German origin participating into the 
population KORAgen study (www.gsf.de/kora/en/english.html). This survey represents a 
gender- and age stratified random sample of all German residents of the Augsburg area and 
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consists of individuals 25 to 74 years of age, with about 300 subjects for each 10-year 
increment. All controls were free of a history of stroke or transient ischemic attack. 
 
Besta Stroke Study (Milano) 
This study includes consecutive Italian patients referred to Besta Institute from 2000 to 2009 
with stroke and included in the Besta Cerebrovascular Diseases Registry (CEDIR). Ischemic 
stroke cases, first ever or recurrent, confirmed on brain imaging, were selected for this study. 
An experienced stroke neurologist assessed all cases. 
 
Australian Stroke Genetics Collaborative (ASGC)  
Stroke cases comprised European-ancestry patients admitted to four clinical centres across 
Australia (The Neurosciences Department at Gosford Hospital, Gosford, New South Wales 
(NSW); the Neurology Department at John Hunter Hospital, Newcastle, NSW; The Queen 
Elizabeth Hospital, Adelaide; and the Royal Perth Hospital, Perth) between 2003 and 2008. 
Stroke was defined by WHO criteria as a sudden focal neurologic deficit of vascular origin, 
lasting more than 24 hours and confirmed by brain imaging. Other investigative tests such as 
electrocardiogram, carotid Doppler and trans-oesophageal echocardiogram were conducted to 
define stroke aetiology as clinically appropriate.  
 
Leuven Stroke Study 
Patients with cerebral ischemia, defined as a clinical stroke with imaging confirmation or a 
TIA with a new ischemic lesion on diffusion weighted MRI, who were admitted to the Stroke 
Unit of the University Hospitals in Leuven were enrolled. All patients underwent brain 
imaging and a standardized protocol including carotid ultrasound or CT angiography and 
cardiac examination (echocardiography and Holter monitoring) in all patients. 
Control individuals were selected from the same population and were either spouses of 
patients with multiple sclerosis, amyotrophic lateral sclerosis or stroke or healthy community 
dwelling subjects partially from the Leuven University Gerontology Database. Controls 
either confirmed they never had a stroke or TIA or responded negative to any item of the 
Verification of Stroke Free Status questionnaire. 
 
GENESIS 
This study recruited patients attending cerebrovascular services at St. George’s Hospital, 
London between 2011-2013. All patients had clinically relevant diagnostic workup 
performed, including brain imaging with magnetic resonance imaging (MRI) as well as 
ancillary diagnostic investigations including duplex ultrasonography of the carotid and 
vertebral arteries, echocardiography, 
Holter monitoring, magnetic resonance angiography (MRA), CT-angiography 
(CTA) and blood tests 
 
WTCCC2-Immunochip 
 
Bio-Repository of DNA in Stroke (BRAINS): London 
The Bio-Repository of DNA in Stroke (BRAINS) is an international study recruiting highly 
phenotyped patients with stroke. For the purposes of the current work all patients were 
Caucasians. Diagnosis of stroke was confirmed using positive imaging (MRI or CT) and 
ischemic stroke subtypes were assigned using TOAST criteria, based on clinical, imaging and 
risk factor data. The cohort has been described in detail elsewhere (Yadav S, Schanz R, 
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Maheshwari A, et al. Bio-Repository of DNA in stroke (BRAINS): a study protocol. BMC 
Med Genet 2011; 12: 34). 
 
Glasgow: Scotland 
Patients with ischemic stroke attending the cerebrovascular service of the Western Infirmary, 
Glasgow, were recruited between 1990 and 2004 as part of an ongoing study of genetic and 
circulating biomarkers in stroke. All patients underwent brain imaging and extracranial 
carotid ultrasound in accordance with a standard clinical protocol. The study was approved 
by the West Ethics Committee.  
 
Controls for the UK samples were drawn from shared WTCCC controls obtained from the 
1958 Birth Cohort. This is a prospectively collected cohort of individuals born in 1958 
(http://www.b58cgene.sgul.ac.uk/), and ascertained as part of the national child development 
study (http://www.cls.ioe.ac.uk/studies.asp?section=000100020003). Data from this cohort 
are available as a common control set for a number of genetic and epidemiological studies. 
 
Lund Stroke Register, Sweden 
Lund Stroke Register (LSR) since 2001 continuously enrolls patients aged 18 and older with 
first-ever stroke, living in the primary uptake area of Skane University Hospital, Lund. The 
study is mainly hospital-based but has a good coverage of the whole geographical 
population.28 All included patients are examined with CT/MR or autopsy of the brain. When 
clinically indicated, the patients are examined with ultrasound imaging of carotid arteries, 
echocardiography, and angiography. In this study, first-ever ischemic stroke patients from 
LSR between 2001 and 2004 were included. All patients were assessed by a neurologically 
trained physician regarding stroke type. Informed consent was obtained from all individuals 
or when they were not able to respond from their next-of-kin. The study was approved by the 
Ethics Committee of Lund University. Biobank services were performed at Region Skane 
Competence Centre (RSKC Malmo), Malmo University Hospital, Malmo, Sweden. 
 
Swedish Control Samples 
Controls for the Lund cases were provided by the Swedish SLE network. Controls were 
healthy blood donors from the geographical areas of Uppsala, Stockholm and Lund. The 
studies were approved by the regional ethics boards and all subjects gave their informed 
consent to participate. Genotyping of the Swedish control samples was performed at the 
SNP&SEQ technology platform in Uppsala, Sweden (www.genotyping.se). 
 
Munich: Germany 
Cases were consecutive European Caucasians recruited from a single dedicated Stroke Unit at 
the Department of Neurology, Klinikum Groβhadern, Ludwig-Maximilians-University, 
Munich. Ischemic stroke subtypes were determined according to TOAST criteria based on 
relevant clinical and imaging data. 
 
German control samples 
German healthy control individuals were obtained from the PopGen biobank [Krawczak et 
al., Community Genet 9:55-61, 2006]. Written, informed consent was obtained from all study 
participants and all protocols were approved by the institutional ethical review committee of 
the participating centre. The panel is a cross-sectional control cohort from the Kiel area in 
Northern Germany. More than 300 phenotypes were collected for the cohort and a 3-year 
follow has recently been completed. All data and biomaterials are accessible via the PopGen 
biobank. The Genotyping was part of the German National Genome Research Network 
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(NGFN) GWAS initiative and performed by the Institute of Clinical Molecular Biology 
(Christian-Albrechts-University of Kiel). 
 
Poland:Krakow 
Patients were recruited in the stroke unit of the Jagiellonian University in Krakow, Poland (a 
single-center study). All stroke patients and controls were >18 years of age and were white. 
All patients had clinically relevant diagnostic workup performed, including brain imaging 
with computed tomography (CT) (100%) and/or magnetic resonance imaging (MRI) (8%) as 
well as ancillary diagnostic investigations including duplex ultrasonography of the carotid 
and vertebral arteries (85.2%), echocardiography (54.8%). MR-angiography, CT-angiography 
Holter monitoring, transesophageal echocardiography and blood tests for hypercoagulability 
were performed were indicated. Patients were classified into etiologic subtypes according to 
the Trial of Org 10172 in Acute Stroke Treatment (TOAST). 
The control group included unrelated subjects taken from the population of southern Poland. 
Control subjects had no apparent neurological disease based on the findings in a structured 
questionnaire and a neurological examination. The study was approved by local research 
ethics committees and informed consent was obtained from all participants. 
 
 
White Matter Hypertensities collaboration International Stroke Genetics Consortium 
 
St Georges University of London (SGUL) 
This study recruited patients attending cerebrovascular services at St. George’s Hospital, 
London between 2007-2011. All patients had clinically relevant diagnostic workup 
performed, including brain imaging with magnetic resonance imaging (MRI) as well as 
ancillary diagnostic investigations including duplex ultrasonography of the carotid and 
vertebral arteries, echocardiography, 
Holter monitoring, magnetic resonance angiography (MRA), CT-angiography 
(CTA) and blood tests 
 
Massachusetts General Hospital (MGH) 
Cases presenting with ischemic stroke and admitted to the Massachusetts General Hospital 
(MGH) Stroke Unit through the Emergency Department, or evaluated in the MGH Neurology 
outpatient clinics, as well as on the inpatient Medical and Vascular Surgical services from 
January 2003 to July 2008. Ischemic stroke was defined as either (1) a radiographically 
proven (head CT or MRI) infarct associated with the appropriate clinical stroke syndrome, or 
(2) a fixed neurological deficit persisting more than 24 hours, consistent with a vascular 
pattern of involvement and without radiographic evidence of demyelinating or other non-
vascular disease. All subjects were evaluated by a neurologist upon presentation and clinical 
and laboratory data were collected during the admission for qualifying ischemic stroke event.  
All patients had acute brain imaging as well as ancillary diagnostic investigations: cervical 
and intracranial vessel imaging using CT or MR angiography (75%), cervical ultrasound 
(24%), echocardiography (86%), and Holter monitoring (16%).  
 
Ischemic Stroke Genetics Study (ISGS) 
Ischemic Stroke Genetics Study (ISGS) was a 5-center, prospective, case-control study of 
first-ever ischemic stroke cases in the United States. All affected individuals had WHO-
defined stroke confirmed by a study neurologist to be ischemic on the basis of head CT or 
brain MRI. Peripheral blood DNA samples were collected between May 2003 and September 
2008.  
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Sibling with Ischaemic Stroke Study (SWISS) 
This is a prospective, multicentre study of sibling pairs with first-ever or recurrent ischemic 
stroke. Probands were recruited from 70 clinical centres across the US and Canada. Ischemic 
stroke affected and unaffected siblings were recruited primarily using proband-initiated 
contact. All affected individuals had WHO-defined stroke confirmed by a study neurologist 
to be ischemic on the basis of brain imaging. Peripheral blood DNA samples were collected 
between October 2000 and December 2009.  
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Appendix 
 
UK Young Lacunar Stroke DNA Study collaborators 
Study managers: Josie Monaghan; Alan Zanich, Samantha Febrey, Eithne Smith, Jenny 
Lennon, St George’s University of London 
 
Participating centres (number of enrolled patients per centre; local investigators): 
Aberdeen Royal Infirmary, Aberdeen (12; Mary Macleod). Addenbrooke’s Hospital, 
Cambridge (54; Jean-Claude Baron, Elizabeth Warburton, Diana J Day, Julie White). 
Airedale General Hospital, Steeton (4; Samantha Mawer). Barnsley Hospital, Barnsley (3; 
Mohammad Albazzaz, Pravin Torane, Keith Elliott, Kay Hawley). Bart’s and the London, 
London (2; Patrick Gompertz). Basingstoke and North Hampshire Hospital, Basingstoke (13; 
Elio Giallombardo, Deborah Dellafera). Blackpool Victoria Hospital, Blackpool (11; Mark 
O'Donnell). Bradford Royal Infirmary, Bradford (1; Chris Patterson). Bristol Royal 
Infirmary, Bristol (8; Sarah Caine). Charing Cross Hospital, London (12; Pankaj Sharma). 
Cheltenham General and Gloucester Royal Hospitals, Cheltenham and Gloucester (10; 
Dipankar Dutta). Chesterfield Royal Hospital, Chesterfield (4; Sunil Punnoose, Mahmud 
Sajid). Countess of Chester Hospital, Chester (22; Kausik Chatterjee). Derriford Hospital, 
Plymouth (4; Azlisham Mohd Nor). Dorset County Hospital NHS Foundation Trust, 
Dorchester (6; Rob Williams). East Kent Hospitals University NHS Foundation Trust, Kent 
(22; Hardeep Baht, Guna Gunathilagan). Eastbourne District General Hospital, Eastbourne 
(4; Conrad Athulathmudali). Frenchay Hospital, Bristol (1; Neil Baldwin). Frimley Park 
Hospital NHS Foundation Trust, Frimley (6; Brian Clarke). Guy’s and St Thomas’ Hospital, 
London (14; Tony Rudd). Institute of Neurology, London (25; Martin Brown). James Paget 
University Hospital, Great Yarmouth (1; Peter Harrison). King's College Hospital, London 
(16; Lalit Kalra). Leeds Teaching Hospitals NHS Trust, London (125; Ahamad Hassan). 
Leicester General Hospital and Royal Infirmary, Leicester (9; Tom Robinson, Amit Mistri). 
Luton and Dunstable NHSFT University Hospital, Luton (16; Lakshmanan Sekaran, 
Sakthivel Sethuraman, Frances Justin). Maidstone andTunbridge Wells NHS Trust (3; Peter 
Maskell). Mayday University Hospital, Croydon (14; Enas Lawrence). Medway Maritime 
Hospital, Gillingham (5; Sam Sanmuganathan). Milton Keynes Hospital, Milton Keynes (1; 
Yaw Duodu). Musgrove Park Hospital, Taunton (9; Malik Hussain). Newcastle Hospitals 
NHS Foundation Trust, Newcastle upon Tyne (12; Gary Ford). Ninewells Hospital, Dundee 
(5; Ronald MacWalter). North Devon District Hospital, Barnstaple (8; Mervyn Dent). 
Nottingham University Hospitals, Nottingham (17; Philip Bath, Fiona Hammonds). Perth 
Royal Infirmary, Perth (2; Stuart Johnston). Peterborough City Hospital, Peterborough (1; 
Peter Owusu-Agyei). Queen Elizabeth Hospital, Gateshead (5; Tim Cassidy, Maria Bokhari). 
Radcliffe Infirmary, Oxford (5; Peter Rothwell). Rochdale Infirmary, Rochdale (4; Robert 
Namushi). Rotherham General Hospital, Rotherham (1; James Okwera). Royal Cornwall 
Hospitals NHS Trust, Truro (11; Frances Harrington, Gillian Courtauld). Royal Devon and 
Exeter Hospital, Exeter (22; Martin James). Royal Hallamshire Hospital, Sheffield (1; 
Graham Venables). Royal Liverpool University Hospital and Broadgreen Hospital, Liverpool 
(9; Aravind Manoj). Royal Preston Hospital, Preston (18; Shuja Punekar). Royal Surrey 
County Hospital, Guildford (23; Adrian Blight, Kath Pasco). Royal Sussex County Hospital, 
Brighton (14; Chakravarthi Rajkumar, Joanna Breeds). Royal United Hospital, Bath (6; 
Louise Shaw, Barbara Madigan). Salford Royal Hospital, Salford (16; Jane Molloy). 
Southampton General Hospital, Southampton (1; Giles Durward). Southend Hospital, 
Westcliff-on-Sea (26; Paul Guyler). Southern General Hospital, Glasgow (34; Keith Muir, 
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Wilma Smith). St George’s Hospital, London (108; Hugh Markus). St Helier Hospital, 
Carshalton (10; Val Jones). Stepping Hill Hospital, Stockport (4; Shivakumar 
Krishnamoorthy). Sunderland Royal Hospital, Sunderland (1; Nikhil Majumdar). The Royal 
Bournemouth Hospital, Bournemouth (15; Damian Jenkinson). The Walton Centre, Liverpool 
(15; Richard White). Torbay Hospital, Torquay (19; Debs Kelly). University Hospital 
Aintree, Liverpool (19; Ramesh Durairaj). University Hospital of North Staffordshire, Stoke-
on-trent (16; David Wilcock). Wansbeck General Hospital and North Tyneside Hospital, 
Ashington and North Shields (6; Christopher Price). West Cumberland Hospital, Whitehaven 
(6; Olu Orugun, Rachel Glover). West Hertfordshire Hospital, Watford (20; David Collas). 
Western General Hospital, Edinburgh (12; Cathie Sudlow). Western Infirmary, Glasgow (33; 
Kennedy R. Lees, Jesse Dawson). Wycombe Hospital and Stoke Mandeville, High Wycombe 
(20; Dennis Briley and Matthew Burn). Yeovil District Hospital, Yeovil (46; Khalid Rashed). 
York Teaching Hospital, York (1; John Coyle).  
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Table I Stroke cohorts 
 
Cohort N Mean age (sd) % Male % Hypertensive 
DNA Lacunar & GENESIS     
Lacunar stroke 998 57.3 (9.6) 704 (71%) 705 (71%) 
Large artery stroke 64 70.1 (11.6) 44 (69%)  
Cardioembolic stroke 80 73.5 (14.6) 47 (59%)  
Controls 970 59.7 (4.3) 510 (53%) NA 
MCLSC     
Lacunar stroke 319 68.5 (11.8) 190 (60%) 262 (82%) 
Large artery stroke 1338 68.9 (11.9) 904 (68%) 906 (68%) 
Cardioembolic stroke 1094 73.7 (13.8) 558 (51%) 761 (70%) 
Controls 7623 62.5 (10.2) 4002 (52%) NA 
LSS      
Lacunar stroke 42 65.5 (13.9) 29 (69%) 26 (62%) 
Large artery stroke 70  43 (61%) 48 (69%) 
Cardioembolic stroke 157  96 (61%) 98 (62%) 
Controls 455 55.7 (14.5) 212 (47%) NA 
WTCCC2-Immunochip 
  
  
Large artery stroke 352 69.1 (12.2) 220 (62%) 234 (67%) 
Cardioembolic stroke 639 75.7 (11.8) 339 (53%) 417 (67%) 
Controls 5401  NA 2304 (43%) NA 
Abbreviations: DNA Lacunar, UK Young Lacunar Stroke DNA Study; GENESIS, Genetic Risk 
factors for Leukoaraiosis study; MCLSC, MRI-confirmed lacunar stroke collaboration; LSS, Leuven 
Stroke Study, WTCCC2-Immunochip, Wellcome Trust Case-Control Consortium II Immunochip  
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Table II WMH study populations 
 
Centre Country N Mean age (sd) % Male % Hypertensive 
Milano Italy 151 57 (14) 60% 57% 
WTCCC2-Edinburgh UK 64 68 (13) 50% 72% 
WTCCC2-Munich FLAIR Germany 447 66 (12) 66% 72% 
WTCCC2-Munich T2 Germany 203 67 (12) 55% 67% 
WTCCC2-Oxford Flair UK 65 65 (15) 54% 65% 
WTCCC2-Oxford T2 UK 75 67 (13) 59% 68% 
WTCCC2-SGUL UK 323 70 (14) 63% 77% 
GENESIS 1  UK 121 67 (14) 67% 62% 
GENESIS 2 UK 228 69 (15) 58% 76% 
SGUL 1 UK 70 70 (13) 61% 61% 
SGUL 2 UK 57 68 (14) 58% 72% 
DNA Lacunar UK 303 57 (9) 72% 68% 
LSS Belgium 361 66 (15) 58% 59% 
MGH-Affymetrix US 476 67 (14) 60% 64% 
MGH-Omni US 84 64 (15) 63% 68% 
MGH-Illumina US 228 66 (15) 64% 61% 
ASGC Australia 96 65 (13) 57% 77% 
ISGS US 207 68 (14) 62% 61% 
SWISS US 111 66 (11) 48% 74% 
Overall   3670       
Abbreviations: Milano, Besta Stroke Register; WTCCC2, The Wellcome Trust Case-Control 
Consortium II; GENESIS, Genetic Risk factors for Leukoaraiosis study; SGUL, St Georges 
University of London; DNA Lacunar, UK Young Lacunar Stroke DNA Study; LSS, Leuven Stroke 
Study; MGH, Massachusetts General Hospital; ASGC, Australian Stroke Genetics Collaborative; 
ISGS, Ischemic Stroke Genetics Study; SWISS, Sibling with Ischaemic Stroke Study  
 
 
